Lilly to Acquire Merida Biosciences for $2.9 Bn
By
Eli Lilly and Company has agreed to acquire Merida Biosciences, a Cambridge, Massachusetts-based clinical-stage bio/pharmaceutical company advancing precision therapeutics for autoimmune and allergic diseases, for $2.875 billion. Merida is developing…
